Is dual immunotherapy needed in first-line treatment of microsatellite instability (MSI)-high metastatic colorectal cancer?

Arora, Sukeshi Patel; Dinesan, Saranya; Cheedella, Naga K S; Pandita, Shruti

Arora, Sukeshi Patel; Dinesan, Saranya; Cheedella, Naga K S; Pandita, Shruti.

Afiliación

Arora SP; Division of Hematology/Oncology, Department of Medicine, Mays Cancer Center, University of Texas Health San Antonio, San Antonio, TX, USA.
Dinesan S; Division of Hematology/Oncology, Department of Medicine, Mays Cancer Center, University of Texas Health San Antonio, San Antonio, TX, USA.
Cheedella NKS; Division of Hematology/Oncology, Department of Medicine, Mays Cancer Center, University of Texas Health San Antonio, San Antonio, TX, USA.
Pandita S; Division of Hematology/Oncology, Department of Medicine, Mays Cancer Center, University of Texas Health San Antonio, San Antonio, TX, USA.

Ann Palliat Med ; 12(2): 427-430, 2023 03.

Article en En | MEDLINE | ID: mdl-36710653

Asunto(s)

Neoplasias del Colon; Neoplasias Colorrectales; Humanos; Inestabilidad de Microsatélites; Neoplasias Colorrectales/patología; Inmunoterapia

Palabras clave

Immunotherapy; colorectal cancer (CRC); ipilimumab; microsatellite instability (MSI); nivolumab

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Colorrectales / Neoplasias del Colon Límite: Humans Idioma: En Revista: Ann Palliat Med Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google